### **Ratio and Proportion Dosage Calculations 2nd Edition Giangrasso Test Bank**

Full Download: http://testbanklive.com/download/ratio-and-proportion-dosage-calculations-2nd-edition-giangrasso-test-bank/

# **Giangrasso** *Ratio & Proportion Dosage Calculation*, 2/E Chapter 2 Ouestion 1

Type: FIB



Figure A1 - Drug Label for Levitra

Read the label in Figure A1, and find the following information:

Strength of the drug \_\_\_\_\_mg per tablet

### **Standard Text:**

**Correct Answer:** 2.5

Rationale :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Find information on a drug label

Question 2 Type: FIB

Giangrasso, *Ratio & Proportion Dosage Calculation*, 2/E Test Bank Copyright 2013 by Pearson Education, Inc.

# Full download all chapters instantly please go to Solutions Manual, Test Bank site: testbanklive.com



ure A2 - Drug Label for Vibramycin

Read the label in Figure A2, and find the following information:

Strength of the drug \_\_\_\_\_mg/5 mL

**Standard Text:** 

**Correct Answer: 25** 

Rationale :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Find information on a drug label

Question 3 Type: FIB




Figure A3 - Drug Label for Diabinese

Read the label in Figure A3, and find the following information:

Strength of the drug \_\_\_\_\_ mg per tablet

**Standard Text:** 

Correct Answer: 100

**Rationale** :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Find information on a drug label

**Question 4 Type:** FIB



Figure A5 - Drug Label for Alprazolam

Read the label in Figure A5, and find the following information:

Strength of the drug \_\_\_\_\_mg per mL

**Standard Text:** 

Correct Answer: 1

**Rationale** :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Find information on a drug label

Question 5 Type: FIB

A physician's order sheet contains the following entry:

Biaxin (clarithromycin) 7.5 mg/kg p.o. q.12h.

How much of the drug will be administered per dose? \_\_\_\_ mg for every kg of bodyweight

# **Standard Text:**

# Correct Answer: 7.5

# **Rationale** :

# **Global Rationale:**

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Interpret the drug order on a prescription or physician's order

Question 6 Type: FIB

A physician's order sheet contains the following entry:

Trandate (labetalol hydrochloride) 20 mg IV STAT and repeat q.10 minutes as needed to max of 300 mg.

How much of the drug will be administered per dose? \_\_\_\_\_mg

### Standard Text:

**Correct Answer: 20** 

### **Rationale** :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Interpret the drug order on a prescription or physician's order

Question 7 Type: FIB

A physician's order sheet contains the following entry:

Lanoxin (digoxin) 125 mcg p.o. daily.

How much of the drug will be administered per dose? \_\_\_\_\_micrograms

### **Standard Text:**

**Correct Answer:** 125

# **Rationale** :

# **Global Rationale:**

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Interpret the drug order on a prescription or physician's order

Question 8 Type: FIB

A physician's order sheet contains the following entry:

Lasix (furosemide) 20 mg p.o. b.i.d.

a. What is the trade name of the drug to be administered?

b. How much of the drug will be administered per dose? \_\_\_\_ mL or \_\_\_\_mg

c. How often will the drug be administered?

d. What is the route of administration?

# **Standard Text:**

Correct Answer: 2; 20

**Rationale** :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Interpret the drug order on a prescription or physician's order

**Question 9 Type:** FIB

A physician's order sheet contains the following entry:

Paral (*paraldehyde*) 5 mg p.r. stat.

How much of the drug will be administered per dose? \_\_\_\_\_mg

**Standard Text:** 

# **Correct Answer:** 5

**Rationale** :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Interpret the drug order on a prescription or physician's order

Question 10

Type: MCSA

Red	Order	Initial	Exp.	Medication, Dosage,	Hours	9/10/08	9/11/08	9/13/08
Check	Date		Date	Frequency, and Route				
Initial								
	9/10/08	DM	10/10/08	LANOXIN (DIGOXIN)	1000	DM	DM	DM
				0.125MG P.O. DAILY				
	9/10/08	DM	10/10/08	LASIX (FUROSEMIDE) 40	0800	DM	DM	DM
				MGIV STATAND THEN Q				
				AM				
	9/10/08	DM	10/10/08	K-DUR (POTASSIUM	1000	DM	DM	DM
				CHLORIDE) 40 MEQ P.O.				
				DAILY				
	9/12/08	DM	9/19/08	REGLAN	0900			
				(METOCLOPRAMIDE				
				HYDROCHLORIDE) 10 MG				
				AC AND HS				
					1300			DM
					1800			DM
					2200			DM

Figure C1 - MAR

Review the information provided in Figure C1. What medication is given more than once per day?

1. Lanoxin

2. Lasix

**3.** K-dur

4. Reglan

**Correct Answer:** 4

Rationale 1:

Rationale 2:

Rationale 3:

Rationale 4:

Global Rationale: Only Reglan is ordered to be, and has been, administered more than once per day.

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Read a MAR

**Question 11 Type:** MCSA

Red	Order	Initial	Ехр.	Medication, Dosage,	Hours	9/10/08	9/11/08	9/13/08
Check	Date		Date	Frequency, and Route				
Initial								
	9/10/08	DM	10/10/08	LANOXIN (DIGOXIN)	1000	DM	DM	DM
				0.125MG P.O. DAILY				
	9/10/08	DM	10/10/08	LASIX (FUROSEMIDE) 40	0800	DM	DM	DM
				MGIV STAT AND THEN Q				
				AM				
	9/10/08	DM	10/10/08	K-DUR (POTA <i>SS</i> IUM	1000	DM	DM	DM
				CHLORIDE) 40 MEQ P.O.				
_				DAILY				
	9/12/08	DM	9/19/08	REGLAN	0900			
				(METOCLOPRAMIDE				
				HYDROCHLORIDE) 10 MG				
				AC AND HS				
					1300			DM
					1800			DM
					2200			DM

# Figure C1 - MAR

Review the information provided in Figure C1. What medication was given at 8:00 a.m.?

1. Lanoxin

2. Lasix

**3.** K-dur

4. Reglan

**Correct Answer:** 2

Rationale 1:

Rationale 2:

Rationale 3:

Rationale 4:

**Global Rationale:** Lasix was administered at 0800 as indicated in the column titled "hours" on 9/10, 9/11, and 9/12.

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Read a MAR

**Question 12 Type:** MCSA

Red	Order	Initial	Exp.	Medication, Dosage,	Hours	9/10/08	9/11/08	9/13/08
Check	Date		Date	Frequency, and Route				-,,
Initial	2.46		2					
	9/10/08	DM	10/10/08	LANOXIN (DIGOXIN)	1000	DM	DM	DM
	710,00	Dim	10,10,00	0.125MG P.O. DAILY	1000		Lim	Dim
	9/10/08	DM	10/10/08	LASIX (FUROSEMIDE) 40	0800	DM	DM	DM
				MGIV STATAND THEN Q				
				AM				
	9/10/08	DM	10/10/08	K-DUR (POTASSIUM	1000	DM	DM	DM
				CHLORIDE) 40 MEQ P.O.				
				DAILY				
	9/12/08	DM	9/19/08	REGLAN	0900			
				(METOCLOPRAMIDE				
				HYDROCHLORIDE) 10 MG				
				AC AND HS				
					1300			DM
					1800			DM
					2200			DM

Figure C1 - MAR

Review the information provided in Figure C1. What medication is administered intravenously?

1. Lanoxin

2. Lasix

**3.** K-dur

4. Reglan

**Correct Answer:** 2

Rationale 1:

Rationale 2:

Rationale 3:

Rationale 4:

**Global Rationale:** Only Lasix is ordered for IV administration. The other medications are ordered for oral administration.

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Read a MAR

**Question 13 Type:** MCSA

Red	Order	Initial	Ехр.	Medication, Dosage,	Hours	9/10/08	9/11/08	9/13/08
Check	Date		Date	Frequency, and Route				
Initial				1 57				
	9/10/08	DM	10/10/08	LANOXIN (DIGOXIN)	1000	DM	DM	DM
				0.125MG P.O. DAILY				
	9/10/08	DM	10/10/08	LASIX (FUROSEMIDE) 40	0800	DM	DM	DM
				MGIV STAT AND THEN Q				
				AM				
	3							
	9/10/08	DM	10/10/08	K-DUR (POTASSIUM	1000	DM	DM	DM
				CHLORIDE) 40 MEQ P.O.				
				DAILY				
	9/12/08	DM	9/19/08	REGLAN	0900			
				(METOCLOPRA MIDE				
				HYDROCHLORIDE) 10 MG				
				AC AND HS				
					1300			DM
					1800			DM
					2200			DM

# Figure C1 – MAR

Review the information provided in Figure C1. How many doses of Reglan has the client received?

**1.** 1

**2.** 2

**3.** 3

**4.** 4

**Correct Answer:** 3

Rationale 1:

Rationale 2:

Rationale 3:

Rationale 4:

**Global Rationale:** The client has received 3 doses of Reglan administered on 9/12. While 4 doses are ordered per day, the 0900 dose was not given and is most likely due to the order being received

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Read a MAR

**Question 14 Type:** MCSA

Red	Order	Initial	Exp.	Medication, Dosage,	Hours	9/10/08	9/11/08	9/13/08
Check	Date		Date	Frequency, and Route				-,,
Initial	2.46		2					
	9/10/08	DM	10/10/08	LANOXIN (DIGOXIN)	1000	DM	DM	DM
	710,00	Dim	10,10,00	0.125MG P.O. DAILY	1000		Lim	Dim
	9/10/08	DM	10/10/08	LASIX (FUROSEMIDE) 40	0800	DM	DM	DM
				MGIV STATAND THEN Q				
				AM				
	9/10/08	DM	10/10/08	K-DUR (POTASSIUM	1000	DM	DM	DM
				CHLORIDE) 40 MEQ P.O.				
				DAILY				
	9/12/08	DM	9/19/08	REGLAN	0900			
				(METOCLOPRAMIDE				
				HYDROCHLORIDE) 10 MG				
				AC AND HS				
					1300			DM
					1800			DM
					2200			DM

Figure C1 - MAR

Review the information provided in Figure C1. What medication was administered immediately?

1. Lanoxin

2. Lasix

**3.** K-dur

4. Reglan

**Correct Answer:** 2

Rationale 1:

Rationale 2:

Rationale 3:

Rationale 4:

**Global Rationale:** Lasix was ordered for STAT, or immediate, administration and then to be given daily after the STAT dose.

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Read a MAR

**Question 15 Type:** FIB

Medication	Hours	9/11	9/12	9/13	9/14	9/15	9/16	9/17
ampicillin	0600	х	CF	CF	CR	CR		
1gIVPBq.6h.	1200	x	СК	СК	CR	CR		
_	1800	х	СК	СК	СК	СК		
	2400	CF	CR	CR	СК	CF		
digoxin	0900	SS	СК	СК	CR	CR		
0.125 mg p.o.								
daily								
Coumadin	0900	SS	СК	СК	CR	CR		
5 mg p.o. daily								
furosemide	1900	х	х	CK	х	х		
40 mg IM stat.								

# Figure C2 – Portion of a Medication Administration Record

Read the MAR in Figure C2 and find the following information:

How many doses of ampicillin has the patient received?

# **Standard Text:**

**Correct Answer:** 17

**Rationale** :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Read a MAR

# Question 16

Type: FIB

Medication	Hours	11/01	11/02	11/03	11/04	11/05	11/06	11/07
		Sun	Mon	Tues	Wed	Thur	Fri	Sat
amlodipine 5	10:00 a.m.	SL	SL	SL	LK	LK		
mg p.o. daily								
Epogen 2,000	10:00 a.m.	Х	SL	Х	LK	Х		Х
units								
subcutaneously								
three times a								
week (M/W/F)								
Humulin NPH	6:30 a.m.	JL	JL	JL	MW	MW		
insulin U-100								
46 units subcut.								
AC breakfast								
Colace 100 mg	10:00 a.m.	SL	SL	SL	LK	LK		
p.o. b.i.d.	2:00 p.m.	SL	SL	SL	LK	LK		
ace tamino phen								
650 mg p.o.								
p.r.n. Temp								
102°F or higher								

Figure C5 – Portion of a Medication Administration Record

Read the MAR in Figure C5 and find the following information:

How many doses of Epogen has the patient received?

# **Standard Text:**

**Correct Answer:** 2

**Rationale** :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Read a MAR

# **Question 17 Type:** FIB

Medication	Hours	9/11	9/12	9/13	9/14	9/15	9/16	9/17
Ampicillin	0600	Х	CF	CF	CR	CR		
1gIVPB	1200	х	СК	СК	CR	CR		
q.6h.	1800	х	СК	СК	СК	СК		
_	2400	CF	CR	CR	СК	CF		
digoxin 0.125 mg p.o. daily	0900	SS	СК	СК	CR	CR		
Coumadin 5 mg p.o. daily	0900	SS	СК	СК	CR	CR		
furosemide 40 mg IM stat.	1900	x	х	СК	х	х		

Figure C6 – Portion of a Medication Administration Record

Read the MAR in Figure C6 and find the following information:

How many doses of ampicillin has the patient received?

**Standard Text:** 

**Correct Answer:** 12

Rationale :

# **Global Rationale:**

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Read a MAR

Question 18 Type: FIB

#### DOSAGE AND ADMINISTRATION

ZONEGRAN (zonisamide) is recommended as adjunctive therapy for the treatment of partial seizures in adults. Safety and efficacy in pediatric patients below the age of 16 have not been established. ZONEGRAN should be administered once or twice daily, using 25 mg, 50 mg or 100 mg capsules. ZONEGRAN is given orally and can be taken with or without food. Capsules should be swallowed whole.

Adult: over Age 16: The prescriber should be aware that, because of the long half-life of zonisamide, up to two weeks may be required to achieve steady state levels upon reaching a stable dose or following dosage adjustment. Although the regimen described below is one that has been shown to be tolerated, the prescriber may wish to prolong the duration of treatment at the lower doses in order to fully assess the effects of zonisamide at steady state, noting that many of the side effects of zonisamide are more frequent at doses of 300 mg per day and above. Although there is some evidence of greater response at doses above 100–200 mg/day, the increase appears small and formal dose-response studies have not been conducted.

The initial dose of ZONEGRAN should be 100 mg daily. After two weeks, the dose may be increased to 200 mg/day for at least two weeks. It can be increased to 300 mg/day and 400 mg/day, with the dose stable for at least two weeks to achieve steady state at each level. Evidence from controlled trials suggests that ZONEGRAN doses of 100-600 mg/day are effective, but there is no suggestion of increasing response above 400 mg/day (see CLINICAL PHARMACOLOGY, Clinical Studiet subsection). There is little experience with doses greater than 600 mg/day.

Patients with Renal or Hepatic Disease: Because zonisamide is metabolized in the liver and excreted by the kidneys, patients with renal or hepatic disease should be treated with caution, and might require slower titration and more frequent monitoring (see CLINICAL PHARMACOLOGY and PRECAUTIONS).

#### HOW SUPPLIED

ZONEGRAN is available as 25 mg, 50 mg and 100 mg two-piece hard gelatin capsules. The capsules are printed in black with "Eisai" and "ZONEGRAN 25," "ZONEGRAN 50," or "ZONEGRAN 100," respectively. ZONEGRAN is available in bottles of 100 with strengths and colors as follows:

Dosage Strength	Capsule Colors	NDC #
25 mg	White opaque body with white opaque cap.	62856-681-10
50 mg	White opaque body with gray opaque cap.	62856-682-10
100 mg	White opaque body with red opaque cap.	62856-680-10

Figure D1 - Portion of the Package Insert for Zonegran

Read the package insert in Figure D1 and answer the following:

What is the initial recommended maximum adult daily dose of the drug? \_\_\_\_\_mg

### Standard Text:

**Correct Answer:** 100

### **Rationale** :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Giangrasso, *Ratio & Proportion Dosage Calculation*, 2/E Test Bank Copyright 2013 by Pearson Education, Inc.

### Nursing/Integrated Concepts: Learning Outcome: Find information on a package insert

# Question 19

Type: FIB

### RAPTIVA® [efalizumab]

#### For injection, subcutaneous

#### DESCRIPTION

RAPTIVA® (etalizumab) is an immunosuppressive recombinant humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a (1). Etalizumab has a molecular weight of approximately 150 kilodations and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Gentamicin is not detectable in the final product.

RAPTIVA is supplied as a sterile, white to off-white, lyophilized powder in single-use glass vials for subcutaneous (SC) injection. Reconstitution of the single-use vial with 1.3 mL of the supplied sterile water for injection (non-USP) yields approximately 1.5 mL of solution to deliver 125 mg per 1.25 mL (100 mg/mL) of RAPTIVA. The sterile water for injection supplied does not comply with USP requirement for pH. After reconstitution, RAPTIVA is a clear to pele yellow solution with a pH of approximately 6.2. Each single-use vial of RAPTIVA contains 150 mg of etalizumab, 123.2 mg of succese, 6.8 mg of L-histidine hydrochloride monohydrate, 4.3 mg of L-histidine and 3 mg of polysorbate 20 and is designed to deliver 125 mg of etalizumab in 1.25 mL.

#### DOSAGE AND ADMINISTRATION

The recommended dose of RAPTIVA® (efailzumab) is a single 0.7 mg/kg SC conditioning dose followed by weekly SC doses of 1 mg/kg (maximum single dose not to exceed a total of 200 mg).

RAPTIVA is intended for use under the guidance and supervision of a physician. If it is determined to be appropriate, patients may self-inject RAPTIVA after proper training in the preparation and injection technique and with medical follow-up.

#### HOW SUPPLIED

RAPTIVA® (efailzumab) is supplied as a lyophilized, sterile powder to deliver 125 mg of efailzumab per single-use vial.

Each RAPTIVA carton contains four trays. Each tray contains one single-use vial designed to deliver 125 mg of efalizumab, one single-use prefilled diluent syringe containing 1.3 mL sterile water for injection (non-USP), two 25 gauge x 5/8 inch needles, two alcohol prep pads, a package insert with an accompanying patient information insert. The NDC number for the four administration dose pack carton is 50242-058-04.

### Figure D2 - Portion of the Package Insert for Raptiva

Read the package insert in Figure D2 and answer the following:

What is the maximum dosage?\_\_\_\_\_mg

### **Standard Text:**

**Correct Answer:** 200

**Rationale** :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Find information on a package insert

Question 20 Type: FIB

### INDICATIONS AND USAGE

DETROL LA Capsules are once daily extended release capsules indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

### CONTRAINDICATIONS

DETROL LA Capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. DETROL LA is also contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.

### PRECAUTIONS

### General

*Risk of Urinary Retention and Gastric Retention:* DETROL LA Capsules should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention and to patients with gastrointestinal obstructive disorders, such as pyloric stenosis, because of the risk of gastric retention (see CONTRAINDICATIONS).

Controlled Narrow-Angle Glaucoma: DETROL LA should be used with caution in patients being treated for narrow-angle glaucoma.

Reduced Hepatic and Renal Function: For patients with significantly reduced hepatic function or renal function, the recommended dose for DETROL LA is 2 mg daily (see CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations).

### DOSAGE AND ADMINISTRATION

The recommended dose of DETROL LA Capsules are 4 mg daily. DETROL LA should be taken once daily with liquids and swallowed whole. The dose may be lowered to 2 mg daily based on individual response and tolerability, however, limited efficacy data is available for DETROL LA 2 mg (see CLINICAL STUDIES).

For patients with significantly reduced hepatic or renal function or who are currently taking drugs that are potent inhibitors of CYP3A4, the recommended dose of DETROL LA is 2 mg daily (see CLINICAL PHARMACOLOGY and PRECAUTIONS, Drug Interactions).

### HOW SUPPLIED

DETROL LA Capsules 2 mg are blue-green with symbol and 2 printed in white ink. DETROL LA Capsules 4 mg are blue with symbol and 4 printed in white ink. DETROL LA Capsules are supplied as follows:

Bottles of 30		Bottles of 500	
2 mg Capsules	NDC 0009-5190-01	2 mg Capsules	NDC 0009-5190-03
4 mg Capsules	NDC 0009-5191-01	4 mg Capsules	NDC 0009-5191-03
Bottles of 90		Unit Dose Blisters	
2 mg Capsules	NDC 0009-5190-02	2 mg Capsules	NDC 0009-5190-04
4 mg Capsules	NDC 0009-5191-02	4 mg Capsules	NDC 0009-5191-04

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from light.

Figure D3 - Portion of the Package Insert for Detrol LA

Read the package insert in Figure D3, and answer the following:

What is the maximum daily dose? \_\_\_\_\_mg Giangrasso, *Ratio & Proportion Dosage Calculation*, 2/E Test Bank Copyright 2013 by Pearson Education, Inc. **Standard Text:** 

**Correct Answer:** 4

**Rationale** :

**Global Rationale:** 


Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Find information on a package insert

Question 21 Type: FIB

### ORAL SUSPENSION DIURIL® (CHLOROTHIAZIDE)

#### DESCRIPTION

DIURIL' (Chlorothiazide) is a diuretic and antihypertensive. It is 6-chloro-2*H*-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is  $C_7H_6CIN_3O_4S_2$  and its structural formula is:



It is a white, or practically white, crystalline powder with a molecular weight of 295.72, which is very slightly soluble in water, but readily soluble in dilute aqueous sodium hydroxide. It is soluble in urine to the extent of about 150 mg per 100 mL at pH 7.

Oral Suspension DIURIL contains 250 mg of chlorothiazide per 5 mL, alcohol 0.5 percent, with methylparaben 0.12 percent, propylparaben 0.02 percent, and benzoic acid 0.1 percent added as preservatives. The inactive ingredients are D&C Yellow 10, flavors, glycerin, purified water, sodium saccharin, sucrose and tragacanth.

#### INDICATIONS AND USAGE

DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.

DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.

DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Use in Pregnancy. Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia.

#### CONTRAINDICATIONS

Anuria.

Hypersensitivity to this product or to other sulfonamide-derived drugs.

#### Pediatric Use

There are no well-controlled clinical trials in pediatric patients. Information on dosing in this age group is supported by evidence from empiric use in pediatric patients and published literature regarding the treatment of hypertension in such patients. (See DOSAGE AND ADMINISTRATION, Infants and Children.)

#### Geriatric Use

Clinical studies of DIURIL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see WARNINGS).

#### HOW SUPPLIED

No. 3239 — Oral Suspension DIURIL, 250 mg of chlorothiazide per 5 mL, is a yellow, creamy suspension, and is supplied as follows:

NDC 0006-3239-66 bottles of 237 mL.

Storage

Oral Suspension DIURIL: Keep container tightly closed. Protect from freezing, -20°C (-4°F) and store at room temperature, 15-30°C (59-86°F).

Figure D5 - Portion of Package Insert for Aldomet

Read the package insert in Figure D5, and answer the following:

What is the maximum daily dose for children? \_\_\_\_\_mg

# **Standard Text:**

**Correct Answer:** 65

Rationale :

**Global Rationale:** 

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Find information on a package insert

# **Question 22 Type:** MCSA

The physician orders a medication to be administered q8h. The first dose is given at 6:00 a.m. What times will this medication be given throughout the day in military time?

1. 0600h - 1400h - 2200h

**2.** 0600h - 1300h - 2200h

- 3. 0800h 1800h 2400h
- 4. 0200h 1000h -1800h

Correct Answer: 1

Rationale 1:

Rationale 2:

Rationale 3:

Rationale 4:

**Global Rationale:** The medication was administered at 06:00 a.m., which is 0600h in military time. Adding 8 hours to 0600h would be 0600h + 0800h = 1400h in military time. The next dose would be given 8 hours later or 1400h + 0800h = 2200h. The times of administration are 0600h-1400h-2200h.

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Standard?military time

**Question 23 Type:** MCSA

A patient is to receive a medication q.8h. The first dose was administered at 10:00 a.m. Write the time of the next dose using military time.

- **1.** 0600h
- **2.** 1800h
- **3.** 1400h
- **4.** 1600h
- **Correct Answer:** 2
- Rationale 1:
- Rationale 2:
- Rationale 3:
- Rationale 4:

Global Rationale: 10 a.m. and 8 hours = 6 p.m., written in military time is 1800h

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Standard?military time

**Question 24 Type:** FIB

A patient is to receive a medication every twelve hours. The first dose was administered at 2100h. At what time will the next dose be administered (expressed as standard time)? \_\_\_\_\_ a.m. on the next day

# Standard Text:

# **Correct Answer:** 9

**Rationale** :

# **Global Rationale:**

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Standard?military time

**Question 25 Type:** MCSA

The client receives nimodipine at 2200h and is to receive the next dose in four hours. At what time, written as standard time, will the next dose be administered?

**1.** 1:00 a.m.

**2.** 2:00 a.m.

**3.** 4:00 a.m.

**4.** 4:00 p.m.

**Correct Answer:** 2

Rationale 1:

**Rationale 2**:

Rationale 3:

Rationale 4:

**Global Rationale:** The medication was administered at 2200h which is 10:00 p.m. 4 hours later would be 02:00 a.m.

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Standard?military time

**Question 26 Type:** MCSA

If an IV starts at 1800 hours and lasts for 12 hours, at what time will it finish? (Express in standard time.)

### **Ratio and Proportion Dosage Calculations 2nd Edition Giangrasso Test Bank**

Full Download: http://testbanklive.com/download/ratio-and-proportion-dosage-calculations-2nd-edition-giangrasso-test-bank/ 1.8 a.m.

2.8 p.m.

**3.** 6 a.m.

**4.** 6 p.m.

**Correct Answer:** 3

Rationale 1:

**Rationale 2**:

**Rationale 3**:

Rationale 4:

Global Rationale: 1800h is 6 p.m. 12 hours later is 6 a.m.

Cognitive Level: Client Need: Client Need Sub: Nursing/Integrated Concepts: Learning Outcome: Standard?military time